Clinical Trial

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-08-01; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2025-10-27
Trial Details
NCT Number NCT07101094
Lead Sponsor Bristol-Myers Squibb
Conditions Schizophrenia
Enrollment 300 participants
Start Date 2025-09-22
Primary Completion 2029-01-31 (estimated)
Study Completion 2029-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-21